Literature DB >> 35229260

Heterodimeric RGD-NGR PET Tracer for the Early Detection of Pancreatic Cancer.

Lingyi Sun1,2, Yongkang Gai3, Zhonghan Li4, Huiqiang Li3, Jianchun Li3, John Muschler5, Rui Kang6, Daolin Tang6, Dexing Zeng7,8.   

Abstract

PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is the most lethal gastrointestinal cancer, and its poor prognosis is highly associated with the lack of an efficient early detection technology. Here, we report that RGD-NGR heterodimer labeled with PET isotope could be applied in PDAC early detection. PROCEDURES: The RGD-NGR tracer was first compared with its corresponding monomeric counterparts via PET imaging studies using mice bearing a subcutaneous BxPC3 tumor. Subsequently, the RGD-NGR tracer was evaluated in autochthonous mouse models with spontaneously developed late stage PanIN lesions (KCER mice) or PDAC (KPC mice) via both PET imaging studies and ex vivo biodistribution studies. Furthermore, a comparison between 2-deoxy-2[18F]fluoro-D-glucose ([18F]F-FDG) and the RGD-NGR tracer was conducted via PET imaging of the same KCH mouse bearing spontaneously developed PDAC. H&E staining was performed to confirm the malignant pancreatic tissue in the KCH mouse. Immunofluorescence staining was performed to confirm the expression of integrin αVβ3 and CD13.
RESULTS: The RGD-NGR tracer exhibited improved in vivo performance as compared with its corresponding monomeric counterparts on the subcutaneous BxPC3 tumor mouse model. Subsequent evaluation in autochthonous mouse models demonstrated its capability to detect both pre-malignant and malignant pancreases. Further comparison with [18F]F-FDG revealed the superiority of the proposed heterodimer in imaging spontaneously developed PDAC. H&E staining confirmed the malignant pancreatic tissue in the KCH mouse, while the expression of both integrin αVβ3 and CD13 receptors was demonstrated with immunofluorescence staining.
CONCLUSION: The proposed RGD-NGR heterodimer possesses the potential to be applied in the PDAC early detection for high-risk populations.
© 2022. World Molecular Imaging Society.

Entities:  

Keywords:  CD13; Early detection; Integrin αVβ3; PET; Pancreatic cancer

Mesh:

Substances:

Year:  2022        PMID: 35229260     DOI: 10.1007/s11307-022-01704-6

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.484


  36 in total

1.  Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine.

Authors:  Everardo D Saad; Marcel C Machado; Dalia Wajsbrot; Roberto Abramoff; Paulo M Hoff; Jacques Tabacof; Artur Katz; Sergio D Simon; René C Gansl
Journal:  Int J Gastrointest Cancer       Date:  2002

Review 2.  Epidemiology of pancreatic cancer: an overview.

Authors:  P Ghadirian; H T Lynch; D Krewski
Journal:  Cancer Detect Prev       Date:  2003

3.  Cancer Statistics, 2021.

Authors:  Rebecca L Siegel; Kimberly D Miller; Hannah E Fuchs; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2021-01-12       Impact factor: 508.702

Review 4.  Imaging techniques in the evaluation of adenocarcinoma of the pancreas.

Authors:  R E Brand; A Matamoros
Journal:  Dig Dis       Date:  1998 Jul-Aug       Impact factor: 2.404

Review 5.  Imaging of small pancreatic ductal adenocarcinoma.

Authors:  J Ariyama; M Suyama; K Satoh; J Sai
Journal:  Pancreas       Date:  1998-04       Impact factor: 3.327

6.  Clinicopathological aspects of small pancreatic cancer.

Authors:  Shinichi Egawa; Kazunori Takeda; Shoji Fukuyama; Fuyuhiko Motoi; Makoto Sunamura; Seiki Matsuno
Journal:  Pancreas       Date:  2004-04       Impact factor: 3.327

Review 7.  Update on pancreatic cancer.

Authors:  Caio Max S Rocha Lima; Barbara Centeno
Journal:  Curr Opin Oncol       Date:  2002-07       Impact factor: 3.645

Review 8.  Epidemiology of pancreatic cancer.

Authors:  D S Michaud
Journal:  Minerva Chir       Date:  2004-04       Impact factor: 1.000

9.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.

Authors:  Sunil R Hingorani; Emanuel F Petricoin; Anirban Maitra; Vinodh Rajapakse; Catrina King; Michael A Jacobetz; Sally Ross; Thomas P Conrads; Timothy D Veenstra; Ben A Hitt; Yoshiya Kawaguchi; Don Johann; Lance A Liotta; Howard C Crawford; Mary E Putt; Tyler Jacks; Christopher V E Wright; Ralph H Hruban; Andrew M Lowy; David A Tuveson
Journal:  Cancer Cell       Date:  2003-12       Impact factor: 31.743

10.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.

Authors:  John P Neoptolemos; Deborah D Stocken; Helmut Friess; Claudio Bassi; Janet A Dunn; Helen Hickey; Hans Beger; Laureano Fernandez-Cruz; Christos Dervenis; François Lacaine; Massimo Falconi; Paolo Pederzoli; Akos Pap; David Spooner; David J Kerr; Markus W Büchler
Journal:  N Engl J Med       Date:  2004-03-18       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.